Senseonics Receives European Approval for Eversense 365, World's Longest-lasting Continuous Glucose Monitor
Senseonics Holdings, Inc. to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Senseonics Announces Preliminary Unaudited Revenue for Fourth Quarter 2025 and Provides Business Update
Senseonics Announces First Commercial Patients Using Eversense 365 Continuous Glucose Monitor with twiist Automated Insulin Delivery System
Senseonics Holdings, Inc. Schedules Third Quarter 2025 Earnings Release and Conference Call for November 5, 2025 at 4:30 P.M. Eastern Time
Senseonics Announces Preliminary Unaudited Revenue for Third Quarter 2025 and Provides Business Update
Senseonics Signs Memorandum of Understanding with Ascensia Diabetes Care to Take Over Commercialization and Distribution of Eversense 365
